AMENDMENTS TO THE CLAIMS

Claims 1-66 (cancelled)

67. (currently amended) A method of administering a biologically active protein to a subject, the method comprising

topically applying to the skin or epithelium of the subject the <u>biologically active</u> protein in conjunction with <u>a carrier in an effective amount for transdermal delivery of the biologically active proteinof a carrier,</u>

wherein the carrier comprises comprising a a polypeptide polymeric backbone having attached positively charged branching groups comprising a sequence of amino acid residues,

wherein the positively charged branching groups are selected from the group consisting of –(gly)_{nl}-(arg)_{n2}, (gly)_p-RGRDDRRQRRR-(gly)_q (SEQ ID NO. 2), (gly)_p-YGRKKRRQRRR-(gly)_q (SEQ ID NO. 3), (gly)_p-RKKRRQRRR-(gly)_q (SEQ ID NO. 4), and Antennapedia protein transduction domain (PTD),

wherein the subscript n1 is an integer of from 0 to about 20, and the subscript n2 is independently an odd integer of from about 5 to about 25.

wherein the subscripts p and q are each independently an integer of from 0 to 20, and

wherein the association between the carrier and the biologically active protein is non-covalent.

- 68. (currently amended) [[A]] <u>The</u> method according to claim 66, wherein the eomposition carrier provides greater transdermal delivery of the biologically active protein relative to the agent biologically active protein in the absence of the carrier.
- 69. (currently amended) [[A]] <u>The</u> method according to claim 68. <u>wherein</u> in which the biologically active protein has therapeutic activity.

- 70. (currently amended) [[A]] The method according to claim 69, wherein in which the therapeutic protein excludes insulin, botulinum toxins, vascular endothelial growth factor (VEGF), and antibody fragments.
- 71. (currently amended) [[A]] <u>The</u> method according to claim 69, wherein in which the therapeutic protein does not therapeutically alter blood glucose levels.
- 72. (currently amended) [[A]] <u>The method according to claim 69. in which wherein the therapeutic protein excludes [[a]] botulinum toxin.</u>
- 73. (currently amended) [[A]] <u>The</u> method according to claim 69 in which the therapeutic protein excludes antibody fragments.
- 74. (currently amended) [[A]] <u>The</u> method according to claim 69 in which the therapeutic protein excludes VEGF.

Claims 75-191 (cancelled).